Refine by
Radiation Therapy Articles & Analysis: Older
121 news found
Alfa Chemistry, a globally recognized chemical supplier, has recently announced its expanded range of services for customized synthesis of biotinylation reagents. Biotinylation, a widely used biological technique, involves the covalent attachment of biotin to biomolecules such as proteins, peptides, and nucleic acids. This technique plays a crucial role in various research fields, including ...
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute ...
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a treatment option ...
“Many patients with rising PSA levels following surgery or radiation are at an increased risk of developing metastasis. With ARASTEP, we are optimistic about the potential to help patients at this earlier stage of the disease,” said Tara Frenkl, M.D., Senior Vice President and Head of Oncology Development at Bayer. ...
ByBayer AG
This includes the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for mHSPC. Nubeqa has been developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. ...
ByBayer AG
Secondary endpoints included time to castration-resistant prostate cancer (CRPC), time to pain progression, time to first symptomatic skeletal event (SSE), time to initiation of subsequent anticancer therapy, all evaluated at 12-week intervals, as well as adverse events (AEs) as a measure of safety and tolerability. ...
ByBayer AG
This includes the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for mHSPC. Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. ...
ByBayer AG
PC treatments include surgery and radiation therapy, bringing added risks of urinary incontinence and erectile dysfunction. ...
Secondary endpoints included time to castration-resistant prostate cancer (CRPC), time to pain progression, time to first symptomatic skeletal event (SSE), time to initiation of subsequent anticancer therapy, all evaluated at 12-week intervals, as well as adverse events (AEs) as a measure of safety and tolerability. ...
ByBayer AG
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announces entry into a sponsored research agreement with Stanford School of Medicine and the appointment of Frederick M. Dirbas, MD, Associate Professor of Surgery, Division of Surgical Oncology, Stanford School of Medicine ...
A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. ...
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
ByxCures
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to ...
BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat tumors with minimal impact on the patient's quality of life compared to other available treatment options, such as radiation, chemotherapy or biological treatment modalities. ...
Miller and Marshall Pitz, describe the activity of LNP-siSAT1 against the GB cells and its ability to further sensitized them towards radiation and chemotherapy providing an avenue to increase treatment efficacy and hence potentially increase survival. ...
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release. The meetings featuring CTT presentations include the American Society of Clinical ...
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas BetaGlue Technologies has appointed four new managers, strengthening the team across strategic fields for its business development: Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni joined the company in September in the ...
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...